John Graham, BSc
CEO and Chairman
John is a seasoned senior executive with extensive experience in building global companies and franchises. John’s three decades of global executive and leadership experience includes 18 years with Aventis, where he held responsibilities in Germany, Mexico, Latin America and the United States. Among other things, while at Aventis, John orchestrated the global strategy and development for the company’s multi-billion dollar diabetes franchise. John played an instrumental role in the development and launch of the blockbuster oral antidiabetic Amaryl, as well as the launch of Lantus, the first long-acting insulin analogue that has transformed diabetes therapy and the world’s leading insulin brand. Since leaving Aventis, John has held senior executive positions at Genzyme Corporation, and Ernst & Young.
John was most recently Chief Executive Officer of the Invida Group, a pan-Asian specialty pharma company, which was acquired by the Menarini Group in 2011. After leaving Menarini in 2015 he joined Torreya Partners, a New York based M&A advisory firm, as a Senior Advisor.
John has a BSc in Biochemistry from Imperial College of Science and Technology, London.
David Malka, BA
Co-Founder, EVP Operations
David is a co-founder of Integrity Applications and has served as our Vice President of Operations since 2003. Prior to co-founding Integrity, David served as a vice president of operations for Solid Systems from 2000 to 2003. From 1994 to 2000, David served as a manager of production and purchasing at Kollmorgen-Servotronix, an Israeli company specializing in the design, development, and manufacture and import of digital servo control systems. From 1991 to 1993, David was a production designer at TFL Time & Frequency Systems Ltd.
David holds a degree in practical engineering – industrial management from the Institute of Work & Production Productivity, Tel-Aviv as well as a B.A. in Management from the Open University of Israel.
Chief Commercial Officer
David is a seasoned pharmaceutical and life sciences executive with more than 20 years of experience in global commercial leadership, most notably with insulin-based therapies. Before joining Integrity Applications, he served at Ernst & Young as Senior Consultant and Subject Matter Expert, Life Sciences, where he assisted major pharmaceutical, animal health, diagnostic, and medical device companies in developing innovative go-to-market commercial strategies, sales and marketing excellence programs, product launch roadmaps, commercial operations and analytics support, and enhanced patient and physician support services.
Previously, David was Senior Director of Global Commercial Effectiveness at Aventis Pharmaceuticals, where he designed and established leading practices in sales and marketing capabilities in the US, Europe, Asia and Latin America. Earlier in his career, David served in various capacities at Hoechst Marion Roussel Inc., including senior commercial leadership positions in both pharmaceutical and consumer healthcare products, most notably in diabetes.
David holds a BS in Marine Biology and Animal Behavior and an MBA in Management at McGill University.
Sami Sassoun, CPA, USA, BA
Chief Financial Officer
Appointed as CFO in February 2017, Sami is responsible for Integrity’s Finance and Accounting. Sami brings an extensive background in corporate finance and fund-raising, financial controls and operations, audit, accounting and investor relations to the company. His experience spans public accounting, investment banking and growth-stage companies in the US, Europe and Israel. Sami joins Integrity Applications from Bedrock Enterprises, a boutique consulting firm that he founded. Previously he held the position of chief financial officer for multiple public and private companies in several industries. Sami began his career as an accountant with Cohn Reznick, an accounting, tax and advisory firm, followed by vice president of finance and operations with Brean Murray & Co, an investment banking firm based in New York City.
Sami obtained his Certified Public Accountant certificate in 1992, and holds a B.S. in accounting from Rutgers University.
Eugene Naidis, MSc.
VP of R&D
Eugene Naidis has an extensive experience in software development and management of R&D projects. Over the past 15 years, he has lead complex projects in the field of industrial and medical measurement devices and applications. Eugene was involved (software development and management) in the invention of a symbiotic approach, revolutionary vibration-based percussion technology to determine the presence of content inside pipes; electromagnetic based, high-precision thickness measurement system; a system for non-contact, continuous measurement of liquid and solid levels in storage containers, based on ultrasonic technology.
Eugene holds BSc. in Metallurgy Engineering and Masters of Science in Metallurgy and Computer Engineering.
Ron Roobroeck, MSc.BM, MBA
Director of International Marketing and Sales
Ron brings over 20 years of international experience in general management, marketing, sales, corporate strategic planning and business development in the pharmaceutical, medical devices, biotech and diagnostic field, managing €60 million turnovers. Before joining Integrity, Ron worked for leading pharmaceutical and medical devices companies such as Novartis, Roche, Medtronic, Cyberonics and Terumo, and gathered experience in the EMEA-JAPAC region and Canada in a B2B, B2C, and B2G environment. Ron is a result driven visionary leader, experienced in organizational change and continuous improvement. Ron holds a Master of Science in Biomedical Kinesiology, and in Rehabilitation Sciences and Physiotherapy, both from the University of Leuven, Belgium.
Ron obtained the Executive MBA at the Vlerick Business School, Belgium, and followed business management classes at INSEAD, France and the London Business School, UK. Ron speaks fluently Dutch, English and French and has a good understanding of German.